









Mercado
/
Acciones
/
nasdaq-pfe
/

Pfizer Inc

PFE

25.680USD

-0.590-2.25%

Cierre 10/08, 16:00（ET）Cotizaciones retrasadas 15 min

145.99BCap. mercado

13.58P/E TTM



Pfizer Inc

25.680

-0.590-2.25%

Descripción general Compañía Finanzas Análisis

Descripción general

Compañía

Finanzas

Análisis

Más Datos de Pfizer Inc Compañía

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

Información de Pfizer Inc



Símbolo de cotizaciónPFE

Nombre de la empresaPfizer Inc

Fecha de salida a bolsaJan 17, 1944

Director ejecutivoDr. Albert Bourla, Ph.D.

Número de empleados81000

Tipo de seguridadOrdinary Share

Fin del año fiscalJan 17

Dirección66 Hudson Boulevard East

CiudadNEW YORK

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal10001-2192

Teléfono12127332323

Sitio Webhttps://www.pfizer.com/

Símbolo de cotizaciónPFE

Fecha de salida a bolsaJan 17, 1944

Director ejecutivoDr. Albert Bourla, Ph.D.

Ejecutivos de Pfizer Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Albert Bourla, Ph.D.

Chairman of the Board, Chief Executive Officer

372.89K

+10.54%

Mr. Douglas M. Lankler

Executive Vice President, Chief Legal Officer

161.04K

+8.26%

Ms. Sally Susman

Executive Vice President, Chief Corporate Affairs Officer

95.94K

+8.23%

Mr. Michael (Ike) Mcdermott

Executive Vice President, Chief Global Supply Officer

70.77K

-0.78%

Mr. Ronald E. Blaylock

Independent Director

32.46K

+149.67%

Ms. Lidia L. Fonseca

Executive Vice President, Chief Digital and Technology Officer

30.96K

Mr. Aamir Malik

Executive Vice President, Chief US Commercial Officer

29.55K

+7800.53%

Ms. Payal Sahni

Executive Vice President, Chief People Experience Officer

24.85K

+6.62%

Mr. Cyrus Taraporevala

Independent Director

10.00K

Dr. Scott Gottlieb, M.D.

Independent Director

10.00K

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Albert Bourla, Ph.D.

Chairman of the Board, Chief Executive Officer

372.89K

+10.54%

Mr. Douglas M. Lankler

Executive Vice President, Chief Legal Officer

161.04K

+8.26%

Ms. Sally Susman

Executive Vice President, Chief Corporate Affairs Officer

95.94K

+8.23%

Mr. Michael (Ike) Mcdermott

Executive Vice President, Chief Global Supply Officer

70.77K

-0.78%

Mr. Ronald E. Blaylock

Independent Director

32.46K

+149.67%

Ms. Lidia L. Fonseca

Executive Vice President, Chief Digital and Technology Officer

30.96K

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por negocioUSD

Nombre

Ganancia

Proporción

Eliquis alliance revenues and direct sales

2.00B

13.67%

Vyndaqel family

1.61B

11.02%

Prevnar family

1.38B

9.44%

All other Hospital

1.09B

7.42%

Oncology-Ibrance

1.05B

7.16%

Otro

7.52B

51.29%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

8.89B

60.70%

Developed Markets

3.39B

23.16%

Emerging Markets

2.37B

16.15%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Eliquis alliance revenues and direct sales

2.00B

13.67%

Vyndaqel family

1.61B

11.02%

Prevnar family

1.38B

9.44%

All other Hospital

1.09B

7.42%

Oncology-Ibrance

1.05B

7.16%

Otro

7.52B

51.29%

Estadísticas de accionistas

Actualizado: vie., 15 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

9.33%

State Street Global Advisors (US)

5.21%

BlackRock Institutional Trust Company, N.A.

5.08%

Geode Capital Management, L.L.C.

2.24%

Norges Bank Investment Management (NBIM)

1.65%

Otro

76.48%

Accionistas

Proporción

The Vanguard Group, Inc.

9.33%

State Street Global Advisors (US)

5.21%

BlackRock Institutional Trust Company, N.A.

5.08%

Geode Capital Management, L.L.C.

2.24%

Norges Bank Investment Management (NBIM)

1.65%

Otro

76.48%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

32.83%

Investment Advisor/Hedge Fund

22.82%

Research Firm

3.11%

Pension Fund

2.25%

Bank and Trust

1.84%

Sovereign Wealth Fund

1.75%

Hedge Fund

1.27%

Insurance Company

1.24%

Holding Company

0.05%

Otro

32.83%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

4787

3.82B

67.19%

-100.74M

2025Q2

4945

3.85B

67.75%

-89.09M

2025Q1

5074

3.86B

67.90%

-51.97M

2024Q4

5153

3.84B

67.74%

-83.26M

2024Q3

5005

3.85B

67.99%

-51.77M

2024Q2

5026

3.84B

67.75%

-120.77M

2024Q1

5032

3.89B

68.71%

-120.39M

2023Q4

5089

3.97B

70.25%

-96.67M

2023Q3

4952

4.00B

70.89%

-71.80M

2023Q2

4962

4.02B

71.16%

-62.35M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

530.68M

9.33%

+10.10M

+1.94%

Jun 30, 2025

State Street Global Advisors (US)

296.30M

5.21%

-669.22K

-0.23%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

288.89M

5.08%

-2.65M

-0.91%

Jun 30, 2025

Geode Capital Management, L.L.C.

127.47M

2.24%

+1.82M

+1.45%

Jun 30, 2025

Norges Bank Investment Management (NBIM)

93.65M

1.65%

+5.87M

+6.68%

Jun 30, 2025

Wellington Management Company, LLP

77.00M

1.35%

-26.49M

-25.60%

Jun 30, 2025

MFS Investment Management

72.76M

1.28%

-276.04K

-0.38%

Jun 30, 2025

State Farm Insurance Companies

57.59M

1.01%

-158.70K

-0.27%

Jun 30, 2025

BlackRock Asset Management Ireland Limited

54.65M

0.96%

+4.18M

+8.29%

Jun 30, 2025

Charles Schwab Investment Management, Inc.

49.17M

0.86%

+1.14M

+2.36%

Jun 30, 2025

ETFs relacionados



Actualizado: mar., 2 de sep

Nombre

Proporción

Franklin US Dividend Booster Index ETF

128.98%

First Trust NASDAQ Pharmaceuticals ETF

7.17%

First Trust Morningstar Dividend Leaders Index Fund

6.24%

Amplify Weight Loss Drug & Treatment ETF

5.07%

Coastal Compass 100 ETF

4.82%

Invesco Pharmaceuticals ETF

4.82%

WBI Power Factor High Dividend ETF

4.75%

LSV Disciplined Value ETF

4.68%

Vaneck Durable High Dividend ETF

4.38%

iShares U.S. Pharmaceuticals ETF

4.28%

Franklin US Dividend Booster Index ETF

Proporción128.98%

First Trust NASDAQ Pharmaceuticals ETF

Proporción7.17%

First Trust Morningstar Dividend Leaders Index Fund

Proporción6.24%

Amplify Weight Loss Drug & Treatment ETF

Proporción5.07%

Coastal Compass 100 ETF

Proporción4.82%

Invesco Pharmaceuticals ETF

Proporción4.82%

WBI Power Factor High Dividend ETF

Proporción4.75%

LSV Disciplined Value ETF

Proporción4.68%

Vaneck Durable High Dividend ETF

Proporción4.38%

iShares U.S. Pharmaceuticals ETF

Proporción4.28%

Dividendos



Un total de 44.91B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Dec 12, 2024

PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025

Jan 24, 2025

Mar 07, 2025

Jan 24, 2025

Oct 09, 2024

PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024

Nov 08, 2024

Dec 02, 2024

Nov 08, 2024

Jun 26, 2024

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024

Jul 26, 2024

Sep 03, 2024

Jul 26, 2024

Apr 24, 2024

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024

May 10, 2024

Jun 14, 2024

May 09, 2024

Dec 14, 2023

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024

Jan 26, 2024

Mar 01, 2024

Jan 25, 2024

Oct 04, 2023

PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023

Nov 10, 2023

Dec 04, 2023

Nov 09, 2023

Jun 22, 2023

PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Sep 05, 2023 going ex on Jul 27, 2023

Jul 28, 2023

Sep 05, 2023

Jul 27, 2023

Apr 26, 2023

PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Jun 09, 2023 going ex on May 11, 2023

May 12, 2023

Jun 09, 2023

May 11, 2023

Dec 09, 2022

PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Mar 03, 2023 going ex on Jan 26, 2023

Jan 27, 2023

Mar 03, 2023

Jan 26, 2023

Sep 22, 2022

PFE.NB Final Cash Dividend of gross USD 0.4 paid on Dec 05, 2022 going ex on Nov 03, 2022

Nov 04, 2022

Dec 05, 2022

Nov 03, 2022

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

